复方斑蝥注射液联合放化疗治疗局部晚期鼻咽癌的疗效及不良反应  

Efficacy and adverse reactions of compound cantharidin injection combined with radiotherapy and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma

作　　者：龚修云 金风 吴伟莉 李媛媛 龙金华 罗秀玲 陈潇潇 吴碧波 王立敏[2] GONG Xiuyun;JIN Feng;WU Weili;LI Yuanyuan;LONG Jinhua;LUO Xiuling;CHEN Xiaoxiao;WU Bibo;WANG Limin(Department of Head and Neck Oncology,Cancer Hospital of Guizhou Province,the Affiliated Cancer Hospital of Guizhou Medical University,Guizhou Guiyang 550004,China;The First People's Hospital of Guiyang City,Guizhou Guiyang 550002,China)

机构地区：[1]贵州医科大学附属肿瘤医院(贵州省肿瘤医院)头颈肿瘤科,贵州贵阳550004 [2]贵阳市第一人民医院,贵州贵阳550002

出　　处：《现代肿瘤医学》2021年第18期3172-3177,共6页Journal of Modern Oncology

基　　金：贵州省中医药管理局中医药、民族中医药科学技术研究(编号:QZYY-2015-026)。

摘　　要：目的:探讨复方斑蝥注射液联合放化疗在局部晚期鼻咽癌治疗中的应用价值。方法:以我中心2015年7月至2017年4月收治的157例初治局部晚期鼻咽癌患者为研究对象,将其随机分为试验组79例与对照组78例。试验组患者采用复方斑蝥注射液联合同步放化疗,对照组患者行常规同步放化疗治疗。收集临床资料,比较两组患者治疗期间相关不良反应发生率、机体免疫功能变化和近期疗效情况。结果:试验组与对照组的CR、PR、SD、PD差异无统计学意义(P=0.269>0.05),近期有效率(CR+PR)差异存在统计学意义(P=0.001),试验组较优于对照组;进一步分析两组患者的4级不良反应发生率存在统计学差异(P<0.05),两组患者治疗前后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、CD8^(+)、CD19^(+)淋巴细胞计数下降,试验组较对照组下降趋势缓和。结论:局部晚期鼻咽癌在规范抗肿瘤治疗过程中给予复方斑蝥注射液治疗可降低患者治疗期间严重不良反应的发生率,对机体免疫功能可能有一定的保护作用,并在一定程度上可辅助提高疗效,需开展多中心、大样本临床研究进一步证实。Objective:To investigate the value of compound cantharidin injection combined with chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma(NPC).Methods:157 patients with newly diagnosed locally advanced nasopharyngeal carcinoma in Cancer Hospital of Guizhou Province from July 2015 to April 2017 were selected as research.This patients were randomly divided into experimental group(79 cases)and control group(78 cases).Patients in the experimental group were treated with compound cantharidin injection combined with concurrent chemoradiotherapy.Patients in the control group were treated with conventional concurrent chemoradiotherapy.The clinical data of the two groups were collected and compared the incidence of treatment-related adverse events,changes in immune function and short-term efficacy in these patients.Results:There was no significant difference in CR,PR,SD and PD between the experimental group and the control group in the short-term efficacy evaluation(P=0.269>0.05).However,the difference in recent effective rate(CR+PR)was statistically significant(P=0.001).It is suggested that the experimental group is superior to the control group.Further data analysis showed that there was a statistical difference in the incidence of 4-degree adverse reactions(P<0.05).There were statistical differences in CD3^(+),CD4^(+),CD4^(+)/CD8^(+),CD8^(+),CD19^(+)lymphocyte counts between the experimental group and the control group after concurrent chemoradiotherapy and before induction chemotherapy.Compared with the control group,the decline in the experimental group was more gentle.Conclusion:For locally advanced nasopharyngeal carcinoma,the treatment with compound cantharidin injection in the standardized anti-tumor process can reduce the occurrence of serious adverse reactions during the treatment of patients,and may have a certain protective effect on the body's immune function.Moreover,it can help to improve the curative effect to a certain extent,which need to be further confirmed by multi-center,lar

关 键 词：局部晚期鼻咽癌 复方斑蝥注射液 时辰化疗 调强放射治疗 毒副反应 近期疗效 免疫功能 

分 类 号：R739.63[医药卫生—肿瘤]